IRB Protocol vs. RUO Supply: What Every Clinic Owner Needs to Understand Before Engaging With Retatrutide

The two most common frameworks clinic owners encounter when exploring retatrutide are IRB-enrolled research protocols and Research Use Only (RUO) supply. On the surface, both involve obtaining a compound that is not FDA-approved and administering it in a clinical setting. In practice, they are fundamentally different — legally, clinically, and from a liability standpoint.

Research Use Only is an FDA designation that applies to reagents, compounds, and biological materials intended for laboratory research — not for human administration. When a compound is labeled RUO, it means:

• It has not been manufactured under pharmaceutical-grade cGMP standards
• It has not been reviewed or approved for human use
• The manufacturer has no obligation to ensure it meets clinical quality standards
• The FDA has not evaluated its safety or efficacy for any human indication

RUO compounds are appropriate for in vitro studies, animal research, and laboratory analysis. They are not appropriate for administration to human patients — not because of a technicality, but because they are not manufactured to the standards required for safe human use.

An IRB-enrolled research protocol is a formal regulatory framework that authorizes human administration of investigational compounds. The IRB — an Institutional Review Board — is an independent ethics committee that reviews research protocols involving human subjects. IRB approval means:

• An independent ethics board has reviewed your research protocol and determined it is scientifically sound and ethically appropriate
• Your informed consent process has been reviewed and approved
• You have a documented research rationale for administering the compound
• You have ongoing oversight and adverse event reporting obligations
• You are operating within the legal framework that governs human subjects research in the United States

This is the same framework used by academic medical centers, clinical trial sites, and research hospitals. It is not a loophole. It is the actual legal mechanism for authorized human administration of investigational compounds.

Under an IRB protocol:

• You have documented regulatory authorization
• You have a reviewed and approved consent process
• You have ongoing oversight from an independent ethics board
• You have a documented research rationale
• If something goes wrong, you have a defensible legal position

Under RUO supply without an IRB:

• You have no regulatory authorization for human administration
• You have no approved consent framework
• You have no independent oversight
• You have no documented research rationale
• If something goes wrong, you have no legal framework to point to

The difference is not academic. Medical boards investigate. Patients sue. Plaintiff's attorneys are sophisticated about the regulatory landscape. A practice that administered RUO compounds to patients without an IRB framework has no defense that will hold up to scrutiny.

Beyond the legal framework, there is a clinical quality difference that matters for patient safety.

Pharmaceutical-grade compounds manufactured under cGMP standards are subject to rigorous quality controls: identity testing, purity testing, potency testing, sterility testing, and endotoxin testing. The manufacturing process is documented and auditable. Deviations are tracked and investigated.

RUO compounds are not subject to these standards. A compound labeled RUO may be pure and potent — or it may not be. There is no regulatory mechanism ensuring it meets clinical quality standards. When you administer an RUO compound to a patient, you are assuming full responsibility for a quality determination that has not been independently verified.

Compliant integration of retatrutide into a clinical practice means establishing an IRB protocol before any patient administration occurs. It means obtaining supply through channels that provide pharmaceutical-grade quality documentation — certificates of analysis, manufacturing records, and chain of custody documentation. It means maintaining proper informed consent records and adverse event reporting.

This is more work than calling a supplier and placing an order. It is also the only approach that is legally defensible.

If you are considering engaging with retatrutide in your practice, the question is not whether to use an IRB framework. The question is whether you are willing to do the work required to establish one. If the answer is no, the honest assessment is that your practice is not ready to engage with this compound compliantly.

MedClinic Partners works exclusively with IRB-enrolled practices for retatrutide supply. We do not supply RUO compounds for human administration, and we do not work with practices that are not operating under an approved research framework.